Literature DB >> 33166406

Decisional involvement and information preferences of patients with hematologic malignancies.

Kah Poh Loh1, Mazie Tsang2, Thomas W LeBlanc3, Anthony Back4, Paul R Duberstein5, Supriya Gupta Mohile1, Ronald M Epstein1,6,7,8, Heidi D Klepin9, Michael W Becker1, Areej El-Jawahri10, Stephanie J Lee4.   

Abstract

Understanding decisional involvement and information preferences in patients with hematologic malignancies may help to optimize physician-patient communication about treatment decisions and align the decision-making processes with patients' preferences. We described and examined factors associated with preferences of patients with hematologic malignancies for decisional involvement, information sources, and presentation of information. In a multicenter observational study, we recruited 216 patients with hematologic malignancies of any stage from September 2003 to June 2007. Patients were asked about their decisional involvement preferences (Control Preferences Scale), information sources (including most useful source of information), and preferences for their oncologists' presentation of treatment success information. We used multivariate logistic regressions to identify factors associated with decisional involvement preferences and usefulness of information sources (physicians vs nonphysicians). Patient-directed, shared, and physician-directed approaches were preferred in 34%, 38%, and 28% of patients, respectively. Physicians and computer/Internet were the most common information sources; 42% perceived physicians as the most useful source. On multivariate analysis, patients with less than a college education (vs postgraduate education) were less likely to perceive their physician as the most useful source (adjusted odds ratio [AOR], 0.46; 95% confidence interval (CI), 0.21-1.00), whereas patients with acute leukemia (vs other blood cancers) were more likely to perceive their physician as the most useful source (AOR, 2.49; 95% CI, 1.07-5.80). In terms of communicating treatment success rates, 70% preferred ≥1 method(s), and 88% preferred presentation in percentages. Our study suggests that decisional involvement and information preferences vary and should be assessed explicitly as part of each decision-making encounter.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 33166406      PMCID: PMC7656941          DOI: 10.1182/bloodadvances.2020003044

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  47 in total

1.  The MOS social support survey.

Authors:  C D Sherbourne; A L Stewart
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

2.  Communicating probabilistic information to cancer patients: is there 'noise' on the line?

Authors:  H J Sutherland; G A Lockwood; D L Tritchler; F Sem; L Brooks; J E Till
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

Review 3.  Information needs and sources of information among cancer patients: a systematic review of research (1980-2003).

Authors:  Lila J Finney Rutten; Neeraj K Arora; Alexis D Bakos; Noreen Aziz; Julia Rowland
Journal:  Patient Educ Couns       Date:  2005-06

4.  Using visual displays to communicate risk of cancer to women from diverse race/ethnic backgrounds.

Authors:  Sabrina T Wong; Eliseo J Pérez-Stable; Sue E Kim; Steven E Gregorich; George F Sawaya; Judith M E Walsh; A Eugene Washington; Celia P Kaplan
Journal:  Patient Educ Couns       Date:  2012-01-12

5.  Numbers are better than words. Verbal specifications of frequency have no place in medicine.

Authors:  M A Nakao; S Axelrod
Journal:  Am J Med       Date:  1983-06       Impact factor: 4.965

6.  Coping styles, health status and advance care planning in patients with hematologic malignancies.

Authors:  Fausto R Loberiza; Barbara A Swore-Fletcher; Susan D Block; Anthony L Back; Roberta E Goldman; James A Tulsky; Stephanie J Lee
Journal:  Leuk Lymphoma       Date:  2011-08-18

7.  Information giving and receiving in hematological malignancy consultations.

Authors:  Stewart C Alexander; Amy M Sullivan; Anthony L Back; James A Tulsky; Roberta E Goldman; Susan D Block; Susan K Stewart; Maureen Wilson-Genderson; Stephanie J Lee
Journal:  Psychooncology       Date:  2011-02-04       Impact factor: 3.894

8.  Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.

Authors:  Christian Straka; Peter Liebisch; Hans Salwender; Burkhard Hennemann; Bernd Metzner; Stefan Knop; Sigrid Adler-Reichel; Christian Gerecke; Hannes Wandt; Martin Bentz; Tim Hendrik Bruemmendorf; Marcus Hentrich; Michael Pfreundschuh; Hans-Heinrich Wolf; Orhan Sezer; Ralf Bargou; Wolfram Jung; Lorenz Trümper; Bernd Hertenstein; Else Heidemann; Helga Bernhard; Nicola Lang; Norbert Frickhofen; Holger Hebart; Ralf Schmidmaier; Andreas Sandermann; Tobias Dechow; Albrecht Reichle; Brigitte Schnabel; Kerstin Schäfer-Eckart; Christian Langer; Martin Gramatzki; Axel Hinke; Bertold Emmerich; Hermann Einsele
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

9.  Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists.

Authors:  Kah Poh Loh; Supriya G Mohile; Jennifer L Lund; Ronald Epstein; Lianlian Lei; Eva Culakova; Colin McHugh; Megan Wells; Nikesha Gilmore; Mostafa R Mohamed; Charles Kamen; Valerie Aarne; Alison Conlin; James Bearden; Adedayo Onitilo; Marsha Wittink; William Dale; Arti Hurria; Paul Duberstein
Journal:  Oncologist       Date:  2019-04-23

10.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Authors:  Jeffrey E Lancet; Geoffrey L Uy; Jorge E Cortes; Laura F Newell; Tara L Lin; Ellen K Ritchie; Robert K Stuart; Stephen A Strickland; Donna Hogge; Scott R Solomon; Richard M Stone; Dale L Bixby; Jonathan E Kolitz; Gary J Schiller; Matthew J Wieduwilt; Daniel H Ryan; Antje Hoering; Kamalika Banerjee; Michael Chiarella; Arthur C Louie; Bruno C Medeiros
Journal:  J Clin Oncol       Date:  2018-07-19       Impact factor: 44.544

View more
  3 in total

1.  Influencing factors of lung cancer patients' participation in shared decision-making: a cross-sectional study.

Authors:  Ying Wang; Jinna Zhang; Bo Hu; Jizhe Wang; Laixiang Zhang; Xiaohua Li; Xiuli Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-18       Impact factor: 4.322

2.  Treatment decision making (TDM): a qualitative study exploring the perspectives of patients with chronic haematological cancers.

Authors:  Dorothy McCaughan; Eve Roman; Alexandra Smith; Russell Patmore; Debra Howell
Journal:  BMJ Open       Date:  2022-03-29       Impact factor: 2.692

3.  Code status transitions in patients with high-risk acute myeloid leukemia.

Authors:  Hannah R Abrams; Ryan D Nipp; Lara Traeger; Mitchell W Lavoie; Matthew J Reynolds; Nneka N Ufere; Annie C Wang; Kofi Boateng; Thomas W LeBlanc; Areej El-Jawahri
Journal:  Blood Adv       Date:  2022-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.